☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
neck squamous cell carcinoma
Merck's Keytruda (pembrolizumab) Receives EC's Approval as 1L Treatment for Metastatic or Unresectable Recurrent Head and Neck Squ...
November 20, 2019
Merck Reports Result of Keytruda (pembrolizumab) in P-III KEYNOTE-048 Study as a 1L Treatment for Recurrent or Metastatic Head and...
May 31, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.